Reaction

Tonsillitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,143 reports · 119 co-occurring drugs

As of the last recalculation, Tonsillitis appears in 5,143 FAERS reports alongside 119 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 15.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Canakinumab	41	15.5	15.5
Infliximab-Dyyb	83	11.7	11.7
Methimazole	18	9.3	9.3
Secukinumab	330	8.8	8.8
Golimumab	168	8.2	8.2
Valproate Sodium	33	6.5	6.5
Basiliximab	18	6.2	6.2
Infliximab	303	5.9	5.9
Bimekizumab	30	5.7	5.7
Azathioprine	122	5.7	5.7
Fexofenadine	22	5.4	5.4
Ustekinumab	133	5.4	5.4
Palivizumab	20	5.3	5.3
Anti-Thymocyte Globulin (Rabbit)	10	5.0	5.0
Certolizumab Pegol	141	5.0	5.0
Amoxicillin And Clavulanate Potassium	32	4.8	4.8
Etonogestrel And Ethinyl Estradiol	26	4.8	4.8
Ganciclovir	12	4.8	4.8
Methotrexate	447	4.6	4.6
Ganciclovir Sodium	12	4.6	4.6
Ivacaftor	9	4.6	4.6
Adalimumab-Adaz	58	4.5	4.5
Methotrexate Sodium	484	4.3	4.3
Ado-Trastuzumab Emtansine	9	4.3	4.3
Cefuroxime	12	4.3	4.3
Escitalopram Oxalate	75	4.2	4.2
Amoxicillin	78	4.2	4.2
Anakinra	17	4.2	4.2
Adalimumab-Aaty	48	4.1	4.1
Nystatin Ointment	26	4.0	4.0
Nystatin Cream	26	4.0	4.0
Escitslopram	57	4.0	4.0
Vedolizumab	84	4.0	4.0
Valganciclovir Hydrochloride Powder,	12	4.0	4.0
Insulin Glulisine	10	4.0	4.0
Hyoscyamine Sulfate	9	4.0	4.0
Adalimumab-Fkjp	45	4.0	4.0
Naproxen	75	3.9	3.9
Nystatin	26	3.9	3.9
Micafungin Sodium	8	3.8	3.8
Prednisolone	164	3.8	3.8
Prednisolone Oral	164	3.8	3.8
Prednisolone Oral Solution	164	3.8	3.8
Filgrastim	34	3.7	3.7
Mesalamine	49	3.6	3.6
Sumatriptan Succinate	22	3.5	3.5
Ocrelizumab	53	3.5	3.5
Ribociclib	27	3.5	3.5
Ofatumumab	28	3.4	3.4
Adalimumab	552	3.4	3.4
Cetiirizine	35	3.4	3.4
Fluticasone Furoate	10	3.3	3.3
Folic Acid	199	3.3	3.3
Mercaptopurine	14	3.3	3.3
Isoniazid	13	3.3	3.3
Valganciclovir	15	3.2	3.2
Valganciclovir Hydrochloride	15	3.2	3.2
Deferasirox	21	3.2	3.2
Clarithromycin	27	3.2	3.2
Sulfasalazine	61	3.2	3.2
Brentuximab Vedotin	8	3.2	3.2
Azelastine	14	3.2	3.2
Tocilizumab	86	3.1	3.1
Ixekizumab	27	3.0	3.0
Fosaprepitant Dimeglumine	10	2.9	2.9
Cetirizine	55	2.9	2.9
Somatropin	52	2.9	2.9
Piperacillin And Tazobactam	9	2.9	2.9
Isotretinoin	34	2.8	2.8
Eculizumab	37	2.8	2.8
Clobetasol Propionate Ointment Usp, 0.05%	7	2.8	2.8
Aripiprazole Oral	28	2.8	2.8
Aripiprazole Orally Disintegrating	28	2.8	2.8
Clobetasol Propionate	7	2.7	2.7
Hydroxychloroquine Sulfate	61	2.7	2.7
Sirolimus	9	2.7	2.7
Azacitidine For	12	2.7	2.7
Progesterone	15	2.7	2.7
Omalizumab	55	2.6	2.6
Azacitidine	19	2.6	2.6
Cladribine	6	2.5	2.5
Baricitinib	6	2.5	2.5
Oxcarbazepine	20	2.5	2.5
Methylphenidate Hydrochloride	36	2.5	2.5
Etanercept	347	2.4	2.4
Trametinib	14	2.3	2.3
Sumatriptan	21	2.2	2.2
Aprepitant	10	2.2	2.2
Cytarabine	31	2.1	2.1
Pertuzumab	14	2.1	2.1
Selexipag	13	2.0	2.0
Etoposide	36	2.0	2.0
Pegaspargase	6	2.0	2.0
Dexlansoprazole	20	1.9	1.9
Venetoclax	29	1.9	1.9
Abatacept	64	1.9	1.9
Sodium Oxybate	29	1.8	1.8
Fingolimod Hcl	38	1.8	1.8
Eltrombopag Olamine	10	1.8	1.8
Guselkumab	15	1.7	1.7
Romiplostim	6	1.6	1.6
Upadacitinib	32	1.6	1.6
Peginterferon Beta-1A	5	1.5	1.5
Drospirenone And Ethinyl Estradiol	16	1.5	1.5
Clozapine	44	1.4	1.4
Lumacaftor And Ivacaftor	3	1.4	1.4
Natalizumab	62	1.4	1.4
Medroxyprogesterone Acetate	17	1.4	1.4
Daratumumab	13	1.3	1.3
Emicizumab	4	1.3	1.3
Teriflunomide	14	1.3	1.3
Dornase Alfa	6	1.2	1.2
Risankizumab-Rzaa	25	1.2	1.2
Vigabatrin	4	1.1	1.1
Dimethyl Fumarate	32	1.1	1.1
Oxymorphone Hydrochloride	3	1.0	1.0
Alirocumab	6	1.0	1.0
Voxelotor	5	0.9	0.9
Dupilumab	80	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.